KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) EBITDA (2016 - 2025)

Arbutus Biopharma's EBITDA history spans 13 years, with the latest figure at -$7.7 million for Q3 2025.

  • For Q3 2025, EBITDA rose 60.59% year-over-year to -$7.7 million; the TTM value through Sep 2025 reached -$42.3 million, up 44.25%, while the annual FY2024 figure was -$69.6 million, 1.62% up from the prior year.
  • EBITDA for Q3 2025 was -$7.7 million at Arbutus Biopharma, down from $2.5 million in the prior quarter.
  • Across five years, EBITDA topped out at $2.5 million in Q2 2025 and bottomed at -$24.6 million in Q1 2025.
  • The 5-year median for EBITDA is -$18.5 million (2022), against an average of -$16.7 million.
  • The largest annual shift saw EBITDA crashed 39.05% in 2021 before it surged 112.68% in 2025.
  • A 5-year view of EBITDA shows it stood at -$21.5 million in 2021, then rose by 0.25% to -$21.4 million in 2022, then rose by 11.99% to -$18.8 million in 2023, then soared by 33.27% to -$12.6 million in 2024, then soared by 38.9% to -$7.7 million in 2025.
  • Per Business Quant, the three most recent readings for ABUS's EBITDA are -$7.7 million (Q3 2025), $2.5 million (Q2 2025), and -$24.6 million (Q1 2025).